DaVita HealthCare Partners (NYSE:DVA) announced that its board has initiated a stock repurchase program, which authorizes the company to buyback $1.50 billion in outstanding shares on Tuesday, October 10th, EventVestor reports. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Several research firms have recently issued reports on DVA. KeyCorp reissued a “hold” rating on shares of DaVita HealthCare Partners in a report on Tuesday. TheStreet lowered DaVita HealthCare Partners from a “b” rating to a “c+” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reissued a “hold” rating and set a $70.00 target price on shares of DaVita HealthCare Partners in a report on Thursday, August 3rd. Zacks Investment Research raised DaVita HealthCare Partners from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Finally, BidaskClub lowered DaVita HealthCare Partners from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the stock. DaVita HealthCare Partners presently has an average rating of “Hold” and a consensus target price of $66.50.

DaVita HealthCare Partners (DVA) traded up 1.75% during mid-day trading on Wednesday, reaching $55.27. The company had a trading volume of 1,903,022 shares. The stock has a 50 day moving average price of $58.47 and a 200-day moving average price of $63.13. The stock has a market capitalization of $10.57 billion, a P/E ratio of 8.49 and a beta of 0.90. DaVita HealthCare Partners has a 12-month low of $53.58 and a 12-month high of $70.16.

DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Tuesday, August 1st. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.02. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.82 billion. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.01 EPS. Equities analysts anticipate that DaVita HealthCare Partners will post $3.59 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/11/davita-healthcare-partners-dva-to-buyback-1-50-billion-in-shares.html.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.